Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Substack by Two Natural Capital. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 2,580,000 | $322,216,200 | +13% | 1.57% |
| 2. | VenBio Select Advisor Kurt Von Emster | 2,555,555 | $319,163,264 | -15% | 4.65% |
| 3. | Casdin Capital Eli Casdin | 1,073,500 | $134,069,415 | 8.93% | |
| 4. | OrbiMed Advisors Samuel Isaly | 954,500 | $119,207,505 | +48% | 2.16% |
| 5. | Citadel Investment Group Ken Griffin | 926,219 | $115,675,491 | +20% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | 284,034 | 2024-08-16 | Filing | ||
| $134.06 | 18,284 | 278,386 | 2024-08-16 | Filing | ||
| $133.07 | 13,106 | 260,102 | 2024-08-16 | Filing | ||
| $78.81 | 40,000 | Director | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | Director | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $124.84 | 10,500 | 22,840 | 2024-12-12 | Filing | ||
| $125.55 | 1,636 | 5,880 | 2024-12-05 | Filing | ||
| $137.36 | 5,985 | 33,946 | 2024-08-30 | Filing | ||
| $164.52 | 2,549 | 17,129 | 2024-06-25 | Filing | ||
| $163.53 | 3,840 | 19,678 | 2024-06-25 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,816,124 | $850,138,837 | 0.01% | |
| 2. | 6,211,792 | $599,003,103 | 0.01% | |
| 3. | 5,345,785 | $515,482,888 | 0.3% | |
| 4. | 4,741,485 | $457,221,399 | 0.1% | |
| 5. | 4,127,610 | $398,025,433 | 0.07% |
News See All
12 High Growth Large Cap Stocks to Buy Now
BlackRock highlighted that its portfolio managers are broadly optimistic about US equities.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Call Transcript
Operator: Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session.
8 Unstoppable Stocks That Could Make You Richer
In the current climate of extreme market volatility, finding safe and stable investments is challenging.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
7 Best Revenue Growth Stocks to Buy According to Analysts
The Fed recently cut the funds rate by 50 basis points which has been considered a bold move by some analysts while others and most of the market have welcomed it with open arms.
16 Best Mid Cap Growth Stocks To Buy Now
Recent discussions among financial strategists emphasize the current stock market dynamics, particularly regarding the upcoming US elections.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and thank you for standing by. Welcome to the Sarepta Therapeutics Second Quarter 2024 Financial Results Conference Call.
Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics (SRPT) on X (formerly Twittter) by user quantumup. In this article we will summarize the bulls' thesis on SRPT.
Billionaire Hedge Funds
